Search results
Factor VII Deficient Plasma
Measurement of factor VII (FVII / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FVII deficient plasma is required
Factor V Deficient Plasma
Measurement of cactor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor V Deficient Plasma
Measurement of factor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Thrombin (IIa), Human
Recommended for all research protocols where a source of highly purified and characterized (h)-thrombin is necessary, and for studies on anti-thrombin activities.
Thrombin (IIa), Human
Recommended for all research protocols where a source of highly purified and characterized (h)-thrombin is necessary, and for studies on anti-thrombin activities.
Thrombin (IIa), Human
Recommended for all research protocols where a source of highly purified and characterized (h)-thrombin is necessary, and for studies on anti-thrombin activities.
BIOPHEN Heparin anti-IIa (Kinetics)
Assay proposed for the measurement of heparin in research applications.
BIOPHEN Heparin anti-IIa (2-stages) -> SEE NEW REF. 220005
Assay proposed for the measurement of heparin anti-thrombin activity in research applications acc. to Pharmacopoeia.
Factor VIII Deficient Plasma
Measurement of factor VIII (FVIII) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent). For any in vitro protocol or research study where a source of human FVIII deficient plasma is required.
Factor VIII Deficient Plasma
Measurement of actor VIII (FVIII) activity in human citrated plasma using a clotting method, in the presence of cephalin, activator and calcium (aPTT reagent). For any in vitro protocol or research study where a source of human FVIII deficient plasma is required.